Added to YB: 2024-01-26
Pitch date: 2024-01-25
CGON [bullish]
CG Oncology, Inc.
+13.72%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer.
Market Cap
$3.3B
Pitch Price
$36.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
-14.71
P/E
-20.18
EV/Sales
1.2K
Sector
Biotechnology
Category
growth
Show full summary:
CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality
$CGON IPO: Ph3 oncolytic virus for $9.8B NMIBC market, Fast Track & Breakthrough status. BCG shortage tailwind, funded thru H2 '27. $1.1B valuation risky but buyout potential if Ph3 holds. Depends on IPO price & reception.
Read full article (10 min)